BioSpace News Archive

Renexxion LLC announced that the company will present at the Oppenheimer Healthcare Private Company Showcase on Wednesday, October 11th, 2023.

Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announce a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease.

Scalp cooling innovator Dignitana AB announces a sales and marketing partnership with InfuSystem Holdings, Inc., a leading health care service provider facilitating outpatient care for durable medical equipment manufacturers and health care providers in the United States.

Elixir Medical, a developer of disruptive cardiovascular technologies, announced submission to Japan’s Pharmaceutical and Medical Device Agency for the approval of the DynamX® Coronary Bioadaptor System for the treatment of coronary artery disease.

Synthego, a leading provider of genome engineering solutions, announced the launch of its IND-enabling gRNAs, a transformative product offering that revolutionizes the CRISPR-based cell and gene therapy preclinical pipeline.

Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs)

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it has received approval from the Listing Qualifications Department of the Nasdaq Stock Market to transfer the listing of its shares from the Nasdaq Global Market to the Nasdaq Capital Market.

Genentech, a member of the Roche Group, presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi® in babies with pre-symptomatic SMA, aged from birth to 6 weeks.

Orakl Oncology, a precision oncology start-up, announces that it has raised €3 million to develop its techbio platform that integrates best-in-class biology with real-world patient data at scale to accurately model tumors and accelerate oncology drug development.

Skanska has signed an additional contract with RWJBarnabas Health to build an ambulatory care cancer center in Livingston, New Jersey, USA.